Announcements

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Methods and Technologies Development”, which are listed below:

1. “Incidence and Risk Assessment of Capsular Contracture in Breast Cancer Patients following Post-Mastectomy Radiotherapy and Implant-Based Reconstruction”
by Maria Vinsensia, Riccarda Schaub, Eva Meixner, Philipp Hoegen, Nathalie Arians, Tobias Forster, Line Hoeltgen, Clara Köhler, Kristin Uzun-Lang, Vania Batista et al.
Cancers 2024, 16(2), 265; https://doi.org/10.3390/cancers16020265
Available online: https://www.mdpi.com/2072-6694/16/2/265

2. “Expanding Our Knowledge of DICER1 Gene Alterations and Their Role in Thyroid Diseases”
by Maria Cristina Riascos, Anh Huynh, William C. Faquin and Vania Nosé
Cancers 2024, 16(2), 347; https://doi.org/10.3390/cancers16020347
Available online: https://www.mdpi.com/2072-6694/16/2/347

3. “Assessment of Narrow-Band Imaging Algorithm for Video Capsule Endoscopy Based on Decorrelated Color Space for Esophageal Cancer: Part II, Detection and Classification of Esophageal Cancer”
by Yu-Jen Fang, Chien-Wei Huang, Riya Karmakar, Arvind Mukundan, Yu-Ming Tsao, Kai-Yao Yang and Hsiang-Chen Wang
Cancers 2024, 16(3), 572; https://doi.org/10.3390/cancers16030572
Available online: https://www.mdpi.com/2072-6694/16/3/572

4. “Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors”
by Paniz Sabeghi, Paniz Zarand, Sina Zargham, Batis Golestany, Arya Shariat, Myles Chang, Evan Yang, Priya Rajagopalan, Daniel Chang Phung and Ali Gholamrezanezhad
Cancers 2024, 16(3), 576; https://doi.org/10.3390/cancers16030576
Available online: https://www.mdpi.com/2072-6694/16/3/576

5. “Identification of Skin Lesions by Snapshot Hyperspectral Imaging”
by Hung-Yi Huang, Hong-Thai Nguyen, Teng-Li Lin, Penchun Saenprasarn, Ping-Hung Liu and Hsiang-Chen Wang
Cancers 2024, 16(1), 217; https://doi.org/10.3390/cancers16010217
Available online: https://www.mdpi.com/2072-6694/16/1/217

7. “A Comprehensive Investigation of Active Learning Strategies for Conducting Anti-Cancer Drug Screening”
by Priyanka Vasanthakumari, Yitan Zhu, Thomas Brettin, Alexander Partin, Maulik Shukla, Fangfang Xia, Oleksandr Narykov, Michael Ryan Weil and Rick L. Stevens
Cancers 2024, 16(3), 530; https://doi.org/10.3390/cancers16030530
Available online: https://www.mdpi.com/2072-6694/16/3/530

8. “New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine”
by Fernardo Alberca-del Arco, Daniel Prieto-Cuadra, Rocio Santos-Perez de la Blanca, Felipe Sáez-Barranquero, Elisa Matas-Rico and Bernardo Herrera-Imbroda
Cancers 2024, 16(4), 803; https://doi.org/10.3390/cancers16040803
Available online: https://www.mdpi.com/2072-6694/16/4/803

9. “The Rise of Hypothesis-Driven Artificial Intelligence in Oncology”
by Zilin Xianyu, Cristina Correia, Choong Yong Ung, Shizhen Zhu, Daniel D. Billadeau and Hu Li
Cancers 2024, 16(4), 822; https://doi.org/10.3390/cancers16040822
Available online: https://www.mdpi.com/2072-6694/16/4/822

10. “Integrating Artificial Intelligence for Advancing Multiple-Cancer Early Detection via Serum Biomarkers: A Narrative Review”
by Hsin-Yao Wang, Wan-Ying Lin, Chenfei Zhou, Zih-Ang Yang, Sriram Kalpana and Michael S. Lebowitz
Cancers 2024, 16(5), 862; https://doi.org/10.3390/cancers16050862
Available online: https://www.mdpi.com/2072-6694/16/5/862

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Molecular Cancer Biology”, which are listed below:

1. “MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges”
by Anju G. S. Phoolchund and Salim I. Khakoo
Cancers 2024, 16(2), 259; https://doi.org/10.3390/cancers16020259
Available online: https://www.mdpi.com/2072-6694/16/2/259

2. “The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer”
by Qingming Fang
Cancers 2024, 16(2), 331; https://doi.org/10.3390/cancers16020331
Available online: https://www.mdpi.com/2072-6694/16/2/331

3. “Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer”
by Qiao-Hong Chen, Erick Munoz and Dennis Ashong
Cancers 2024, 16(3), 663; https://doi.org/10.3390/cancers16030663
Available online: https://www.mdpi.com/2072-6694/16/3/663

4. “Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells”
by Youssef Al Hmada, Robert T. Brodell, Naji Kharouf, Thomas W. Flanagan, Abdulhadi A. Alamodi, Sofie-Yasmin Hassan, Hosam Shalaby, Sarah-Lilly Hassan, Youssef Haikel, Mosaad Megahed et al.
Cancers 2024, 16(2), 470; https://doi.org/10.3390/cancers16020470
Available online: https://www.mdpi.com/2072-6694/16/2/470

5. “Glioma–Immune Cell Crosstalk in Tumor Progression”
by Mahmoud Elguindy, Jacob S. Young, Isha Mondal, Rongze O. Lu and Winson S. Ho
Cancers 2024, 16(2), 308; https://doi.org/10.3390/cancers16020308
Available online: https://www.mdpi.com/2072-6694/16/2/308

6. “Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review”
by Shigekatsu Maekawa, Ryo Takata and Wataru Obara
Cancers 2024, 16(3), 523; https://doi.org/10.3390/cancers16030523
Available online: https://www.mdpi.com/2072-6694/16/3/523

7. “Characteristics of Cancer Stem Cells and Their Potential Role in Endometrial Cancer”
by Karolina Frąszczak and Bartłomiej Barczyński
Cancers 2024, 16(6), 1083; https://doi.org/10.3390/cancers16061083
Available online: https://www.mdpi.com/2072-6694/16/6/1083

8. “Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer”
by Maciej Jaromin, Tomasz Konecki and Piotr Kutwin
Cancers 2024, 16(7), 1366; https://doi.org/10.3390/cancers16071366
Available online: https://www.mdpi.com/2072-6694/16/7/1366

9. “Transforming Growth Factor-β/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis”
by Julien Boudreault, Ni Wang, Mostafa Ghozlan and Jean-Jacques Lebrun
Cancers 2024, 16(1), 224; https://doi.org/10.3390/cancers16010224
Available online: https://www.mdpi.com/2072-6694/16/1/224

10. “The Tumor Suppressor SOCS1 Diminishes Tolerance to Oxidative Stress in Hepatocellular Carcinoma”
by Akhil Shukla, Md Gulam Musawwir Khan, Anny Armas Cayarga, Mozhdeh Namvarpour, Mohammad Mobarak H. Chowdhury, Dominique Levesque, Jean-François Lucier, François-Michel Boisvert, Sheela Ramanathan and Subburaj Ilangumaran
Cancers 2024, 16(2), 292; https://doi.org/10.3390/cancers16020292
Available online: https://www.mdpi.com/2072-6694/16/2/292

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

MDPI’s Best PhD Thesis Awards are granted to promising young scholars whose PhD theses are deemed exceptional within their respective research fields. These awards aim to encourage young scholars to continue their outstanding accomplishments and further contribute to their field.

We extend our heartfelt congratulations to the 54 winners of the 2023 Best PhD Thesis Awards and wish them success with their future research endeavors.

MDPI will continue to provide support and recognition to the academic community. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:

About MDPI Awards:

To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.

To explore more MDPI awards, please click here.

The 2024 International Conference of the Korean Society for Molecular and Cellular Biology will be held from 8 to 11 October 2024, in Jeju, Republic of Korea. The conference is organized by the Korean Society for Molecular and Cellular Biology, and promises a rich tapestry of scholarly exchange across various disciplines within biological and biomedical sciences.

The conference will feature four top keynote speakers in the field of life sciences, including two Nobel Prize winners, and scientists from more than thirty countries around the world participating in more than twenty scientific sessions on a variety of topics. The agenda includes symposiums showcasing pioneering research in life sciences, dedicated sessions for young academics, such as graduate students, postdoctoral researchers, and research professors, and a Bio Job Fair.

The following MDPI journals will be represented at the conference:

• International Journal of Molecular Sciences;
• Antioxidants;
• Biophysica;
• Current Issues in Molecular Biology;
• Kinases and Phosphatases;
• Metabolites;
• Microorganisms;
• Proteomes;
• Bioengineering;
• Biomedicines;
• BioMed;
• Biomolecules;
• Cancers;
• Genes;
• Journal of Molecular Pathology;
• Organoids;
• Plants;
• Non-Coding RNA;
• Sci;
• Journal of Fungi.

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #99 and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.ksmcb.or.kr/icksmcb2024/main.html.

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers in the Section “Cancer Pathophysiology” from the first half of 2024, which are listed below:

1. “Application of Nanoparticles for Magnetic Hyperthermia for Cancer Treatment—The Current State of Knowledge”
by Marzena Szwed and Agnieszka Marczak
Cancers 2024, 16(6), 1156; https://doi.org/10.3390/cancers16061156
Available online: https://www.mdpi.com/2072-6694/16/6/1156

2. “Machine Learning-Based Assessment of Survival and Risk Factors in Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma for Optimized Patient Management”
by Miguel Suárez, Sergio Gil-Rojas, Pablo Martínez-Blanco, Ana M. Torres, Antonio Ramón, Pilar Blasco-Segura, Miguel Torralba and Jorge Mateo
Cancers 2024, 16(6), 1114; https://doi.org/10.3390/cancers16061114
Available online: https://www.mdpi.com/2072-6694/16/6/1114

3. “MALAT-1 Is a Key Regulator of Epithelial–Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis”
by Mohamed Ali Hussein, Kamyab Valinezhad, Eman Adel and Gnanasekar Munirathinam
Cancers 2024, 16(1), 234; https://doi.org/10.3390/cancers16010234
Available online: https://www.mdpi.com/2072-6694/16/1/234

4. “Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review”
by Haider Ghazanfar, Nismat Javed, Abeer Qasim, George Sarin Zacharia, Ali Ghazanfar, Abhilasha Jyala, Elona Shehi and Harish Patel
Cancers 2024, 16(6), 1214; https://doi.org/10.3390/cancers16061214
Available online: https://www.mdpi.com/2072-6694/16/6/1214

5. “PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma”
by Andrea Ronchi, Gerardo Cazzato, Giuseppe Ingravallo, Giuseppe D’Abbronzo, Giuseppe Argenziano, Elvira Moscarella, Gabriella Brancaccio and Renato Franco
Cancers 2024, 16(2), 278; https://doi.org/10.3390/cancers16020278
Available online: https://www.mdpi.com/2072-6694/16/2/278

6. “17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications”
by Vid Mlakar, Isabelle Dupanloup, Fanny Gonzales, Danai Papangelopoulou, Marc Ansari and Fabienne Gumy-Pause
Cancers 2024, 16(2), 338; https://doi.org/10.3390/cancers16020338
Available online: https://www.mdpi.com/2072-6694/16/2/338

7. “Biomarkers in the Diagnosis of Endometrial Precancers. Molecular Characteristics, Candidate Immunohistochemical Markers, and Promising Results of Three-Marker Panel: Current Status and Future Directions”
by Shuang Niu, Kyle Molberg, Diego H. Castrillon, Elena Lucas and Hao Chen
Cancers 2024, 16(6), 1159; https://doi.org/10.3390/cancers16061159
Available online: https://www.mdpi.com/2072-6694/16/6/1159

8. “Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma”
by Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Richard Stone, William Forrester, Edmund Harrington et al.
Cancers 2024, 16(7), 1319; https://doi.org/10.3390/cancers16071319
Available online: https://www.mdpi.com/2072-6694/16/7/1319

9. “From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist’s Dual Role in Prostate Cancer”
by Abdulrahman Alhajahjeh, Raad Al-Faouri, Hisham F. Bahmad, Taima’ Bader, Ryan W. Dobbs, Ahmed A. Abdulelah, Wassim Abou-Kheir, Elai Davicioni, David I. Lee and Mohammed Shahait
Cancers 2024, 16(8), 1538; https://doi.org/10.3390/cancers16081538
Available online: https://www.mdpi.com/2072-6694/16/8/1538

10. “Significant and Various Effects of ML329-Induced MITF Suppression in the Melanoma Cell Line”
by Nami Nishikiori, Megumi Watanabe, Tatsuya Sato, Masato Furuhashi, Masae Okura, Tokimasa Hida, Hisashi Uhara and Hiroshi Ohguro
Cancers 2024, 16(2), 263; https://doi.org/10.3390/cancers16020263
Available online: https://www.mdpi.com/2072-6694/16/2/263

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Cancer Therapy”, which are listed below:

1. “The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy”
by Corrado Tinterri, Bethania Fernandes, Alberto Zambelli, Andrea Sagona, Erika Barbieri, Simone Di Maria Grimaldi, Shadya Sara Darwish, Flavia Jacobs, Camilla De Carlo, Martina Iuzzolino et al.
Cancers 2024, 16(2), 376; https://doi.org/10.3390/cancers16020376
Available online: https://www.mdpi.com/2072-6694/16/2/376

2. “Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy”
by Ryungsa Kim, Takanori Kin and William T. Beck
Cancers 2024, 16(5), 984; htpps://doi.org/10.3390/cancers16050984
Available online: https://www.mdpi.com/2072-6694/16/5/984

3. “Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials”
by Jinjiang Wang, Jiaxi Li, Jiao Liu, Kit-Ying Chan, Ho-Sze Lee, Kenneth Nansheng Lin, Chi-Chiu Wang and Tat-San Lau
Cancers 2024, 16(3), 512; htpps://doi.org/10.3390/cancers16030512
Available online: https://www.mdpi.com/2072-6694/16/3/512

4. “Targeted Therapeutic Strategies for the Treatment of Cancer”
by Benjamin Victoir, Cécile Croix, Fabrice Gouilleux and Gildas Prié
Cancers 2024, 16(2), 461; htpps://doi.org/10.3390/cancers16020461
Available online: https://www.mdpi.com/2072-6694/16/2/461

5. “Prognosis and Treatment of Gastric Cancer: A 2024 Update”
by Claudia Burz, Vlad Pop, Ciprian Silaghi, Iulia Lupan and Gabriel Samasca
Cancers 2024, 16(9), 1708; htpps://doi.org/10.3390/cancers16091708
Available online: https://www.mdpi.com/2072-6694/16/9/1708

6. “Exploring Helium Ions’ Potential for Post-Mastectomy Left-Sided Breast Cancer Radiotherapy”
by Santa Gabriella Bonaccorsi, Thomas Tessonnier, Line Hoeltgen, Eva Meixner, Semi Harrabi, Juliane Hörner-Rieber, Thomas Haberer, Amir Abdollahi, Jürgen Debus and Andrea Mairani
Cancers 2024, 16(2), 410; htpps://doi.org/10.3390/cancers16020410
Available online: https://www.mdpi.com/2072-6694/16/2/410

7. “Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions”
by Rohan Kalyan Rej, Joyeeta Roy and Srinivasa Rao Allu
Cancers 2024, 16(3), 552; htpps://doi.org/10.3390/cancers16030552
Available online: https://www.mdpi.com/2072-6694/16/3/552

8. “Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma”
by Charles B. Nguyen, Eugene Oh, Piroz Bahar, Ulka N. Vaishampayan, Tobias Else and Ajjai S. Alva
Cancers 2024, 16(3), 601; htpps://doi.org/10.3390/cancers16030601
Available online: https://www.mdpi.com/2072-6694/16/3/601

9. “Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape”
by Emily Kinsey and Hannah M. Lee
Cancers 2024, 16(3), 666; htpps://doi.org/10.3390/cancers16030666
Available online: https://www.mdpi.com/2072-6694/16/3/666

10. “Head-to-Head Comparison of [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in Patients with Triple-Negative Breast Cancer”
by Natalia Andryszak, Daria Świniuch, Elżbieta Wójcik, Rodryg Ramlau, Marek Ruchała and Rafał Czepczyński
Cancers 2024, 16(3), 667; https://doi.org/10.3390/cancers16030667
Available online: https://www.mdpi.com/2072-6694/16/3/667

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

The 37th Annual Congress of the European Association of Nuclear Medicine, organized by the European Association of Nuclear Medicine, will be held from 19 to 23 October 2024, in Hamburg, Germany.

This conference will offer a platform to exchange and discuss the latest theranostic advances, alongside the most impactful clinical evidence, recently developed radiopharmaceuticals, and novel imaging and detection technologies. Several topics will be discussed during the “Technologists’ Track”, including, among many others, whole-body multimodality imaging principles, PET-CT in oncologic disease-staging applications, radio-guided surgery, brain PET studies, and recent advancements regarding artificial intelligence and radiomics, as well as one of the most relevant aspects of healthcare—patient advocacy.

The following MDPI journals will be represented at the conference:

• Diagnostics;
• Neurology International;
• Journal of Clinical Medicine;
• Medicina;
• Cancers;
• Children;
• Imaging;
• Tomography;
• Sci;
• Current Oncology.

If you are attending this conference, please feel free to start a conversation by contacting us online. Our delegates look forward to meeting you in person at our booth and answering any questions that you may have. For more information about the conference, please visit the following link: https://eanm24.eanm.org/.

MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.

We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.

MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:

Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.

About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.

To find out more about MDPI awards, please click here.

As all of the articles published in Cancers (ISSN: 2072-6694) are open access, you have free and unlimited access to the full text of all articles. We welcome you to read our most highly cited papers published in 2023 in the Section “Cancer Pathophysiology”, which are listed below:

1. “Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments”
by Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Christelle Fargette, Michael Baboudjian, Laurence Colleaux, David Taïeb and Palma Rocchi
Cancers 2023, 15(20), 5047; https://doi.org/10.3390/cancers15205047
Available online: https://www.mdpi.com/2072-6694/15/20/5047

2. “Resveratrol-Loaded Polymeric Nanoparticles: The Effects of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) on Physicochemical and Biological Properties against Breast Cancer In Vitro and In Vivo”
by Paulo George Cavalcante de Freitas, Bruno Rodrigues Arruda, Maria Gabriela Araújo Mendes, João Vito Barroso de Freitas, Mateus Edson da Silva, Tiago Lima Sampaio, Raquel Petrilli and Josimar O. Eloy
Cancers 2023, 15(10), 2802; https://doi.org/10.3390/cancers15102802
Available online: https://www.mdpi.com/2072-6694/15/10/2802

3. “Methods to Evaluate Changes in Mitochondrial Structure and Function in Cancer”
by Brittany P. Rickard, Marta Overchuk, Vesna A. Chappell, Mustafa Kemal Ruhi, Prima Dewi Sinawang, Tina Thuy Nguyen Hoang, Demir Akin, Utkan Demirci, Walfre Franco, Suzanne E. Fenton et al.
Cancers 2023, 15(9), 2564; https://doi.org/10.3390/cancers15092564
Available online: https://www.mdpi.com/2072-6694/15/9/2564

4. “How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers?”
by Massimiliano Cani, Fabio Turco, Simona Butticè, Ursula Maria Vogl, Consuelo Buttigliero, Silvia Novello and Enrica Capelletto
Cancers 2023, 15(10), 2836; https://doi.org/10.3390/cancers15102836
Available online: https://www.mdpi.com/2072-6694/15/10/2836

5. “Molecular Alterations in Cutaneous Squamous Cell Carcinoma in Immunocompetent and Immunosuppressed Hosts—A Systematic Review”
by Denise Ann Tsang, Steve Y. C. Tam and Choon Chiat Oh
Cancers 2023, 15(6), 1832; https://doi.org/10.3390/cancers15061832
Available online: https://www.mdpi.com/2072-6694/15/6/1832

6. “Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma”
by Hoi-Hin Kwok, Jiashuang Yang and David Chi-Leung Lam
Cancers 2023, 15(10), 2749; https://doi.org/10.3390/cancers15102749
Available online: https://www.mdpi.com/2072-6694/15/10/2749

7. “Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma”
by Adele M. Alchahin, Ioanna Tsea and Ninib Baryawno
Cancers 2023, 15(19), 4734; https://doi.org/10.3390/cancers15194734
Available online: https://www.mdpi.com/2072-6694/15/19/4734

8. “Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center”
by Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Waldemar Kapusta, Wawrzyniec Żmudzki, Adrianna Mróz, Beata Kos-Kudła and Grzegorz Kamiński
Cancers 2023, 15(22), 5466; https://doi.org/10.3390/cancers15225466
Available online: https://www.mdpi.com/2072-6694/15/22/5466

9. “Radiomics Analysis in Characterization of Salivary Gland Tumors on MRI: A Systematic Review”
by Kaijing Mao, Lun M. Wong, Rongli Zhang, Tiffany Y. So, Zhiyi Shan, Kuo Feng Hung and Qi Yong H. Ai
Cancers 2023, 15(20), 4918; https://doi.org/10.3390/cancers15204918
Available online: https://www.mdpi.com/2072-6694/15/20/4918

10. “Disturbances in Nitric Oxide Cycle and Related Molecular Pathways in Clear Cell Renal Cell Carcinoma”
by Corina Daniela Ene, Mircea Tampa, Simona Roxana Georgescu, Clara Matei, Iulia Maria Teodora Leulescu, Claudia Ioana Dogaru, Mircea Nicolae Penescu and Ilinca Nicolae
Cancers 2023, 15(24), 5797; https://doi.org/10.3390/cancers15245797
Available online: https://www.mdpi.com/2072-6694/15/24/5797

11. “Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs”
by Alice Laffi, Andrea Gerardo Antonio Lania, Alberto Ragni, Valentina Di Vito, Alessia Liccardi, Manila Rubino, Franz Sesti, Annamaria Colao, Antongiulio Faggiano and on behalf of the NIKE Group
Cancers 2023, 15(8), 2202; https://doi.org/10.3390/cancers15082202
Available online: https://www.mdpi.com/2072-6694/15/8/2202

12. “Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions”
by Josh B. Karpes, Raphael Shamavonian, Suzannah Dewhurst, Ernest Cheng, Ru Wijayawardana, Nima Ahmadi and David L. Morris
Cancers 2023, 15(19), 4704; https://doi.org/10.3390/cancers15194704
Available online: https://www.mdpi.com/2072-6694/15/19/4704

13. “The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective”
by Azik Hoffman and Gilad E. Amiel
Cancers 2023, 15(13), 3402; https://doi.org/10.3390/cancers15133402
Available online: https://www.mdpi.com/2072-6694/15/13/3402

14. “Prognostic Value of SGK1 and Bcl-2 in Invasive Breast Cancer”
by Umaima Al-Alem, Garth H. Rauscher, Qais Al Alem, Andre Kajdacsy-Balla and Abeer M. Mahmoud
Cancers 2023, 15(12), 3151; https://doi.org/10.3390/cancers15123151
Available online: https://www.mdpi.com/2072-6694/15/12/3151

15. “Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis”
by Nico C. Grossmann, Francesco Soria, Tristan Juvet, Aaron M. Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita et al.
Cancers 2023, 15(5), 1409; https://doi.org/10.3390/cancers15051409
Available online: https://www.mdpi.com/2072-6694/15/5/1409

You are invited to view and submit relevant papers to the journal Cancers.

Cancers Editorial Office